Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction-Reference-Cited by-同舟云学术

Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction

Published:2015-04-12 Issue:5 Volume:31 Page:687-693
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Hioki Hirofumi,Motoki Hirohiko,Izawa Atsushi,Kashima Yuichirou,Miura Takashi,Ebisawa Souichirou,Tomita Takeshi,Miyashita Yusuke,Koyama Jun,Ikeda Uichi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s00380-015-0673-1/fulltext.html

Reference22 articles.

1. Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357:1385–1390

2. Australia/New Zealand Heart Failure Research Collaborative Group (1997) Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349:375–380

3. Packer M, Soats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658

4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–e292

5. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigi M, van’t Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: An updated systematic review and meta-analysis;Archives of Cardiovascular Diseases;2022-12

2. Long-Term Effect of β-Blocker Use on Clinical Outcomes in Postmyocardial Infarction Patients: A Systematic Review and Meta-Analysis;Frontiers in Cardiovascular Medicine;2022-04-08

3. Prognosis of acute myocardial infarction in patients on hemodialysis stratified by Killip classification in the modern interventional era (focus on the prognosis of Killip class 1);Heart and Vessels;2021-08-04

4. Prognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention;Pharmacological Research;2021-07

5. The selection of β-blocker after successful reperfusion in patients with ST-elevation myocardial infarction;Perfusion;2019-10-14